FDA Fast Tracks AG-221 to Treat AML
the Cancer Therapy Advisor take:
Agios Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has designated AG-221, which is currently undergoing clinical trials, Fast Track status for the treatment of acute myelogenous leukemia (AML) with a positive isocitrate dehydrogenase-2 (IDH2) mutation.
AG-221 is an orally available, selective, potent inhibitor of the IDH2 mutation. Agios Pharmaceuticals initiated a phase 1 multicenter, open-label, dose escalation clinical study of AG-221 to evaluate the safety and tolerability of the drug. IDH2 is an important enzyme utilized during the Krebs cycle, but in many cancers, the enzyme appears to be mutated. By blocking this enzyme in cancer cells, the cancer cells would be destroyed.
The FDA designates certain drugs Fast Track status in order to speed up development and the review of new drugs so that they may be made available to patients sooner. The FDA reserves this designation for medications that treat serious or life-threatening diseases or to fill an unmet medical need.
AML is a type of cancer in which the bone marrow makes abnormal myeloblasts, erythrocytes, or thrombocytes. The disease is known for its rapid disease progression and is the most common form of acute leukemia in adults.
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Currently, AG-221 is being evaluated in a Phase I clinical trial in patients with advanced hematologic malignancies. Agios chief medical officer Dr Chris Bowden said the company believes this designation is an important recognition by the FDA of the nonclinical and clinical data reported to date and the potential for AG-221 to address a significant unmet need for patients diagnosed with AML.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer